drugset / Trial / NCT03170115

Induction Chemotherapy Plus Chemoradiotherapy With or Without Aspirin in High Risk Rectal Cancer

NCT03170115

Phase 2 Terminated 25 enrolled Brazilian National Cancer Institute
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The benefit of aspirin in cancer of the colon and rectum is already known. Recently, it was described its potential activity during chemoradiotherapy, with higher rate of tumor downstaging. Furthermore, induction chemotherapy followed by chemoradiation represents an attractive approach, with more favorable compliance and toxicity profiles. The aim of this study was to evaluate the efficacy of total neoadjuvant treatment and assess the efficacy and feasibility of aspirin use during chemoradiotherapy for high-risk rectal cancer.

Timeline

Start
2017-11-30
Primary completion
2020-01-17
Completion
2020-01-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule 100 mg

Indications